Eisai Co. Ltd. and Purdue Pharma LP have reported positive Phase III data for their insomnia therapy lemborexant from the SUNRISE 1 trial; the drug appears to impact an underlying reason for a patient’s inability to sleep well.
Eisai, Purdue To File Insomnia Drug Following Positive Head-To-Head
Eisai and its partner Purdue are expected to file insomnia drug lemborexant with the US FDA within the next 12 months, following more positive data.
